Abstract
Objectives
Study Design
Results
Conclusions
Implications
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- Development of the selective progesterone receptor modulator CDB-2914 for clinical indications.Steroids. 2003; 68: 1013-1017
- Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days.J Clin Endocrinol Metab. 2002; 87: 63-70
- A novel estrogen-free oral contraceptive pill for women: multicenter double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).Human Reproduction. 2007; 22: 2428-2436
- The selective progesterone receptor modulator ulipristal acetate inhibits the activity of the glucocorticoid receptor.J Clin Endocrin Metab. 2020; 10593: 716-734
- Progesterone receptor modulator for emergency contraception: A randomized controlled trial.Obstet Gynecol. 2006; 108: 1089-1097
- Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis.Lancet. 2010; 375: 60101-60108
- Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel.Contraception. 2011; 84: 363-367
- Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.J Clin Endocrin Metab. 2007; 92: 3582-3589
- Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.Contraception. 2012; 85: 480-488
- A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: Research for a novel estrogen-free method of contraception.Contraception. 2014; 90: 565-574
- Ulipristal acetate versus placebo for fibroid treatment before surgery.N Engl J Med. 2012; 366: 409-420https://doi.org/10.1056/NEJMoa1103182
- Long-term treatment of uterine fibroids with ulipristal acetate.Fertil Steril. 2014; 101 (e1-18): 1565-1573https://doi.org/10.1016/j.fertnstert.2014.02.008
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.MMWR Recomm Rep 2010. 2010; 59: 1-6
Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, et al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017:464-9. doi: 10.1016/j.contraception.2017.01.004
- Ovarian suppression in normal-weight and obese women during oral contraceptive use.Obstet Gynecol. 2010; 117: 275-283
- Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.Contraception. 2009; 80: 119-127
- Liver injury and ulipristal acetate: an overstated tragedy?.Fertil Steril. 2018; 110: 593-595https://doi.org/10.1016/j.fertnstert.2018.06.044
- A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women.Contraception. 2015; 91: 360-367
Article info
Publication history
Footnotes
☆Conflicts of Interest: CW – Consultant to Merck, Bayer, AbbVie, Therapeutics MD, HRAPharma. Research support from Estetra SPRL, Sebela, Chemoresearch Exeltis, and Medicines360, all managed through Columbia University. DA- Consultant to Agile Therapeutics, Mayne, Mithra, TherapeuticsMD. Grants from Bayer Healthcare, Mithra, Myovant, ObsEva, TherapeuticsMD. Investments in Agile Therapeutics, InnovaGyn, Inc. KB- Consultant to Bayer Health Care. PD – no conflicts. MG- no conflicts. JJ – Consultant to Bayer Healthcare, Evofem, Mayne Pharma, Merck, Sebela, and TherapeuticsMD. OHSU has received research support from Abbvie, Bayer Healthcare, Daré, Mayne, Medicines360, Merck, and Sebela. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU. ST – Consultant to Merck and Bayer Healthcare. Research support at University of Colorado from Sebela, Medicines 360, Merck & Co, Bayer Health care, and Chemo Research S.L. AN- Consultant/Advisory Board: Agile Therapeutics, Bayer HealthCare, Mayne Pharma, Pfizer, TherapeuticsMD. Honoraria/Speakers Bureau: Agile Therapeutics, Bayer HealthCare, Mayne Pharma, Myovant Sciences, Organon/Merck & Co., TherapeuticsMD. Grants/Research: Mylan Pharmaceuticals, Myovant Sciences, Organon/Merck & Co., Sagami Rubber Industries, Sebela Pharmaceuticals. MT-Dr. Thomas is the Vice President for ASRM and serves on the Board of Directors for ABOG. DB-NICHD has two Cooperative Research and Development Agreements (CRADAs) with industry, HRA Pharma and Daré, in which Dr. Blithe has served as Principal Investigator. Joint inventions resulting from the CRADA with HRA Pharma have generated royalty payments to NICHD and to Dr. Blithe as a co-inventor of therapeutic indications for Ulipristal Acetate. JB- no conflicts of interest.
Funding: The National Institute of Child Health and Human Development sponsored this study. HRA Pharma supplied the investigational product; HRA Pharma had no involvement with the protocol, study execution, analysis or preparation of this manuscript.
